APA (7th ed.) Citation

N, D., L, M., P, B., M, A., T, D., Y, L., . . . SK, P. (2022). Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: A randomized phase 1 trial. Nature medicine, 28(4), 704. https://doi.org/10.1038/s41591-022-01694-6

Chicago Style (17th ed.) Citation

N, Dizman, et al. "Nivolumab Plus Ipilimumab with or Without Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma: A Randomized Phase 1 Trial." Nature Medicine 28, no. 4 (2022): 704. https://doi.org/10.1038/s41591-022-01694-6.

MLA (9th ed.) Citation

N, Dizman, et al. "Nivolumab Plus Ipilimumab with or Without Live Bacterial Supplementation in Metastatic Renal Cell Carcinoma: A Randomized Phase 1 Trial." Nature Medicine, vol. 28, no. 4, 2022, p. 704, https://doi.org/10.1038/s41591-022-01694-6.